It is unclear to us how to define a "pharmacogenomics fact", and how
much information can be packed into one annotation instead of multiple
annotations. One annotation should only discuss one drug-biomarker pair.
That is clear. However, if a statement discusses both increased
metabolism and increased toxicity, should those be annotated in one
statement, or should two statements be annotated? What is the
granularity we want?
It is unclear to us how to define a "pharmacogenomics fact", and how much information can be packed into one annotation instead of multiple annotations. One annotation should only discuss one drug-biomarker pair. That is clear. However, if a statement discusses both increased metabolism and increased toxicity, should those be annotated in one statement, or should two statements be annotated? What is the granularity we want?